Dosage Form
Dispersible tablet.

Indications
To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefixime and other antibacterial drugs, cefixime should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
EXMOCEF- 200 is indicated in the treatment of patients, with the following infections when caused by susceptible isolates of the designated bacteria:
Uncomplicated Urinary Tract Infections (e.g. cystitis, cystourethritis, uncomplicated pyelonephritis) caused by Escherichia coli and Proteus mirabilis.
Upper Respiratory Tract Infections (URTI) where the causative organism is known or suspected to be resistant to other commonly used antibiotics, or where treatment failure may carry significant risk.
Otitis Media caused by Haemophilusinfluenzae, Moraxella catarrhalis, and Streptococcus pyogenes.
Pharyngitis and Tonsillitis caused by Streptococcus pyogenes.
Cefixime is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx;
Acute Exacerbations of Chronic Bronchitis caused by Streptococcus pneumoniae and Haemophilusinfluenzae.
Uncomplicated Gonorrhoea (cervical/urethral) caused by Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing isolates).

Dosage and Administration
Adults
The recommended adult dosage is 200 to 400 mg daily according to the severity of infection, given either as a single dose or in two divided doses.
For the treatment of uncomplicated cervical/urethral gonococcal infections, a single oral dose of 400 mg is recommended. In the treatment of infections due to Streptococcus pyogenes, a therapeutic dosage of cefixime should be administered for at least 10 days.

Contraindications
Cefixime is contraindicated in patients with a known allergy to cefixime or other cephalosporins or any of the other components of the product.